Literature DB >> 15229094

Invasive aspergillosis in critically ill patients without malignancy.

Wouter Meersseman1, Stefaan J Vandecasteele, Alexander Wilmer, Eric Verbeken, Willy E Peetermans, Eric Van Wijngaerden.   

Abstract

Using criteria designed for invasive aspergillosis (IA) in patients with cancer, we aimed to determine the impact of IA in patients without malignancy in a medical intensive care unit (ICU). In this retrospective study, 127 patients out of 1,850 admissions (6.9%) hospitalized between 2000 and 2003 had microbiological or histopathologic evidence of Aspergillus during their ICU stay. There were 89 cases (70%) without hematologic malignancy. These patients were classified as proven IA (n = 30), probable IA (n = 37), possible IA (n = 2), or colonization (n = 20). In these patients, mean SAPS II score was 52 with a predicted mortality of 48%. The observed mortality was 80% (n = 71). Mortality of the proven and the probable IA was 97 and 87%, respectively. Postmortem examination was done in 46 out of 71 patients, and 27 autopsies (59%) showed hyphael invasion with Aspergillus. Aspergillus infections occurred in five critically ill patients with proven IA who did not have any predisposing factors according to the currently available definitions. Three of these patients had Child C liver cirrhosis. IA is an emerging and devastating infectious disease in patients in the ICU without malignancy. In those patients, host criteria for probable fungal infections should probably be adapted.

Entities:  

Mesh:

Year:  2004        PMID: 15229094     DOI: 10.1164/rccm.200401-093OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  124 in total

1.  Evaluation of serum (1 → 3)-β-D-glucan clinical performance: kinetic assessment, comparison with galactomannan and evaluation of confounding factors.

Authors:  P Pini; C Bettua; C F Orsi; C Venturelli; F Forghieri; S Bigliardi; L Faglioni; F Luppi; L Serio; M Codeluppi; M Luppi; C Mussini; M Girardis; Elisabetta Blasi
Journal:  Infection       Date:  2015-10-16       Impact factor: 3.553

2.  Genetic Diversity and In Vitro Antifungal Susceptibility of 200 Clinical and Environmental Aspergillus flavus Isolates.

Authors:  Mojtaba Taghizadeh-Armaki; Mohammad Taghi Hedayati; Saham Ansari; Saeed Mahdavi Omran; Sasan Saber; Haleh Rafati; Jan Zoll; Henrich A van der Lee; Willem J G Melchers; Paul E Verweij; Seyedmojtaba Seyedmousavi
Journal:  Antimicrob Agents Chemother       Date:  2017-04-24       Impact factor: 5.191

3.  Invasive aspergillosis in the ICU: an emerging disease.

Authors:  Wouter Meersseman; Eric Van Wijngaerden
Journal:  Intensive Care Med       Date:  2007-07-24       Impact factor: 17.440

4.  Gluconate-containing intravenous solutions: another cause of false-positive galactomannan assay reactivity.

Authors:  Ignace Surmont; Willem Stockman
Journal:  J Clin Microbiol       Date:  2007-02-07       Impact factor: 5.948

Review 5.  Cavitary pulmonary disease.

Authors:  L Beth Gadkowski; Jason E Stout
Journal:  Clin Microbiol Rev       Date:  2008-04       Impact factor: 26.132

6.  Defining, treating and preventing hospital acquired pneumonia: European perspective.

Authors:  Antoni Torres; Santiago Ewig; Harmut Lode; Jean Carlet
Journal:  Intensive Care Med       Date:  2008-11-07       Impact factor: 17.440

7.  Pulmonary Aspergillosis in Patients with Suspected Ventilator-associated Pneumonia in UK ICUs.

Authors:  Laura Loughlin; Thomas P Hellyer; P Lewis White; Danny F McAuley; Andrew Conway Morris; Raquel B Posso; Malcolm D Richardson; David W Denning; A John Simpson; Ronan McMullan
Journal:  Am J Respir Crit Care Med       Date:  2020-10-15       Impact factor: 21.405

Review 8.  Disseminated aspergillosis following infliximab therapy in an immunosuppressed patient with Crohn's disease and chronic hepatitis C: a case study and review of the literature.

Authors:  Joel W Alderson; Thomas G Van Dinter; Michael J Opatowsky; Elizabeth C Burton
Journal:  MedGenMed       Date:  2005-09-21

9.  Beta-D-glucan detection as a diagnostic test for invasive aspergillosis in immunocompromised critically ill patients with symptoms of respiratory infection: an autopsy-based study.

Authors:  Greet De Vlieger; Katrien Lagrou; Johan Maertens; Eric Verbeken; Wouter Meersseman; Eric Van Wijngaerden
Journal:  J Clin Microbiol       Date:  2011-08-31       Impact factor: 5.948

10.  [Community-acquired pneumonia].

Authors:  K Dalhoff
Journal:  Internist (Berl)       Date:  2011-09       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.